Association of <i><scp>CD</scp>28</i> and <i><scp>CTLA</scp>4</i> haplotypes with susceptibility to primary Sjögren′s syndrome in Mexican population

López-Villalobos, Erika Fabiola; Carrillo-Ballesteros, Francisco Josué; Muñoz‐Valle, José Francisco; Palafox‐Sánchez, Claudia Azucena; Valle, Yeminia; Orozco‐Barocio, Gerardo

doi:10.1002/jcla.22620

Cited by 6 publications

(9 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of all the patients, 71.56% were women (78/109); the mean age at RA diagnosis was 44.94 ± 14.46 years and the median disease duration was 16 [ 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 ] years; 13.76% (15/109) were smokers. All the patients had been treated with other DMARDs, for a median period of 36 [ 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , …”

Section: Resultsmentioning

confidence: 99%

“…A total of 14.68% (16/109) were ABA-bionaive, 26.61% (29/109) began the treatment after failure of 1 tumor necrosis factor inhibitor (TNFi), 28.44% (31/109) did so after failure of 2 TNFis and 30.28% (33/109) began treatment with ABA after failure of 3 or more TNFis. The mean age at the start of ABA treatment was 56.37 ± 13.05 years, and the median duration of ABA therapy was 28 [ 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 ] months. ABA was administered by SC route in 55.05% (60/109) and by IV route in 44.95% (49/109).…”

Section: Resultsmentioning

confidence: 99%

“…This modulation is performed physiologically by CTLA-4 [ 52 ]. Several SNPs located on this gene have been investigated for their association with autoimmune diseases [ 22 , 23 , 28 , 53 ]. The CTLA-4 rs5742909 polymorphism ( C > T ) is in the promoter region of exon 1 of the CTLA-4 gene, affecting the ATG transcription initiation codon [ 54 ].…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, SNPs in the CTLA-4 gene have been associated with peripheral tolerance. CTLA-4 is an immune system regulatory receptor, constituently expressed on the surface of activated T lymphocytes and in regulatory T lymphocytes, inhibiting their proliferation [ 22 , 23 , 24 ]. CTLA-4 shows a greater affinity for the CD80/CD86 complex than CD28 and activates an immune signal inhibiting T-lymphocyte proliferation.…”

Section: Introductionmentioning

confidence: 99%

“…CTLA-4 shows a greater affinity for the CD80/CD86 complex than CD28 and activates an immune signal inhibiting T-lymphocyte proliferation. It is indispensable for terminating the immune response cascade, as well as for acquisition of peripheral tolerance for antigens, preventing autoimmunity [ 23 , 25 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Impact of Single-Nucleotide Polymorphisms of CTLA-4, CD80 and CD86 on the Effectiveness of Abatacept in Patients with Rheumatoid Arthritis

Pete

Montoro

Ramírez

et al. 2020

JPM

View full text Add to dashboard Cite

Abatacept (ABA) is used as a first-line treatment in patients diagnosed with moderate and severe rheumatoid arthritis (RA). The interindividual response to ABA therapy is very variable in these patients. The objective of our study was therefore to investigate the role of polymorphisms of the CTLA-4, CD80 and CD86 genes, as well as that of clinical factors of the disease, in the response to ABA in patients with RA. A retrospective cohort study was carried out in 109 patients receiving treatment with ABA and diagnosed with RA. The genetic variables were analyzed using real-time PCR with TaqMan® probes. The patients were classified according to the European League Against Rheumatism (EULAR) criteria at 6 and 12 months from start of treatment. The independent variables associated with higher EULAR response were lower duration of previous biologic disease-modifying anti-rheumatic drugs and lower baseline values of the disease activity score 28 after 6 months of ABA treatment; and lower baseline patient’s visual analogue scale (PVAS) after 12 months. In addition, a significant association was found between duration of ABA treatment, non-administration of concomitant glucocorticoids and lower baseline values of the number of inflamed joints and erythrocyte sedimentation rate clinical variables, with remission of the disease after 6 months’ treatment with ABA. Finally, remission of the disease after 12 months’ treatment with ABA was associated with earlier age at start of ABA therapy and lower number of previous biologic therapies (BTs). The CTLA-4rs5742909-T allele and the CTLA-4rs231775-G allele were found to be associated with satisfactory EULAR response and low disease activity (LDA) after 12 months’ treatment with ABA (CTLA-4rs5742909 T vs. CC; OR = 5.88; CI95% = 1.48–23.29 and OR = 4.75; CI95% = 1.35–17.94, respectively, and CTLA-4rs231775 G vs. AA, OR = 3.48; CI95% = 1.20–10.09 and OR = 4.68; CI95% = 1.49–17.94, respectively). In conclusion, patients with RA treated with ABA showed better EULAR response and LDA rate when they had the CTLA-4 rs5742909-T or CTLA-4 rs231775-G polymorphisms; furthermore, this remission rate increased in patients that began ABA treatment earlier, those with a lower number of previous BTs and those with a lower PVAS value.

show abstract